• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IVVD alert in real time by email
    SC 13D/A 1 d896430dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)

     

     

    INVIVYD, INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    00534A102

    (CUSIP Number)

    Lauren Crockett

    Polaris Partners

    One Marina Park Drive, 8th Floor

    Boston, MA 02210

    (781) 290-0770

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 10, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Venture Partners V, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     3,120,194 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     3,120,194 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,120,194 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     2.6% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All shares are held of record by Polaris V (as defined in Item 2(a) of the Original Schedule 13D). PVMC V (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Polaris V and may be deemed to have shared voting, investment and dispositive power with respect to these securities. The PVMC V Managing Members (as defined in Item 2(c) of the Original Schedule 13D) are the managing members of PVMC V and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris V.

    (2)

    Based on 119,616,035 shares of Common Stock (as defined in Item 1 of the Original Schedule 13D) outstanding as of November 1, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q for the quarter ended September 30, 2024, filed with the United States Securities and Exchange Commission (the “Commission”) on November 14, 2024 (the Form 10-Q).


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Venture Partners Entrepreneurs’ Fund V, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     60,814 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     60,814 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     60,814 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.1% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All shares are held of record by Polaris EF V (as defined in Item 2(a) of the Original Schedule 13D). PVMC V is the general partner of Polaris EF V and may be deemed to have shared voting, investment and dispositive power with respect to these securities. The PVMC V Managing Members are the managing members of PVMC V and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris EF V.

    (2)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q.


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Venture Partners Founders’ Fund V, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     21,374 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     21,374 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     21,374 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.0% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All shares are held of record by Polaris FF V (as defined in Item 2(a) of the Original Schedule 13D). PVMC V is the general partner of Polaris FF V and may be deemed to have shared voting, investment and dispositive power with respect to these securities. The PVMC V Managing Members are the managing members of PVMC V and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris FF V.

    (2)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q.


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Venture Partners Special Founders’ Fund V, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     31,198 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     31,198 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     31,198 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.0% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All shares are held of record by Polaris SFF V (as defined in Item 2(a) of the Original Schedule 13D). PVMC V is the general partner of Polaris SFF V and may be deemed to have shared voting, investment and dispositive power with respect to these securities. The PVMC V Managing Members are the managing members of PVMC V and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris SFF V.

    (2)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q.


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Venture Management Co. V, L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     3,233,580 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     3,233,580 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,233,580 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     2.7% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    Consists of: (i) 3,120,194 shares held of record by Polaris V, (ii) 60,814 shares held of record by Polaris EF V, (iii) 21,374 shares held of record by Polaris FF V and (iv) 31,198 shares held of record by Polaris SFF V. PVMC V is the general partner of each of Polaris V, Polaris EF V, Polaris FF V and Polaris SFF V and may be deemed to have shared voting, investment and dispositive power with respect to these securities. The PVMC V Managing Members are the managing members of PVMC V and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Polaris V, Polaris EF V, Polaris FF V and Polaris SFF V.

    (2)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q.


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Partners IX, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     4,202,679 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     4,202,679 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,202,679 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     3.5% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All shares are held of record by Polaris IX (as defined in Item 2(a) of the Original Schedule 13D). PPGP IX (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Polaris IX and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Terrance McGuire, an interest holder in PPGP IX and a member of the Issuer’s Board (as defined in the Original Schedule 13D), and the PPGP IX Managing Members (as defined in Item 2(c) of the Original Schedule 13D) are the managing members of PPGP IX and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris IX.

    (2)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q.


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Partners GP IX, L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     4,202,679 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     4,202,679 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,202,679 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     3.5% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    All shares are held of record by Polaris IX. PPGP IX is the general partner of Polaris IX and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Terrance McGuire, an interest holder in PPGP IX and a member of the Issuer’s Board, and the PPGP IX Managing Members are the managing members of PPGP IX and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris IX.

    (2)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q.


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Healthcare Technology Opportunities Fund, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     497,660 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     497,660 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     497,660 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.4% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All shares are held of record by Polaris HCT (as defined in Item 2(a) of the Original Schedule 13D). PHCT GP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Polaris HCT and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Terrance McGuire, an interest holder in PHCT GP and a member of the Issuer’s Board, and the PHCT GP Managing Members (as defined in Item 2(c) of the Original Schedule 13D) are the managing members of PHCT GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris HCT.

    (2)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q.


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Polaris Healthcare Technology Opportunities Fund GP, L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     497,660 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     497,660 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     497,660 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     0.4% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    All shares are held of record by Polaris HCT. PHCT GP is the general partner of Polaris HCT and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Terrance McGuire, an interest holder in PHCT GP and a member of the Issuer’s Board, and the PHCT GP Managing Members are the managing members of PHCT GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris HCT.

    (2)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q.


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Terrance McGuire

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     160,593 (1)

        8  

     SHARED VOTING POWER

     

     7,933,919 Shares of Common Stock (2)

        9  

     SOLE DISPOSITIVE POWER

     

     160,593 (1)

       10  

     SHARED DISPOSITIVE POWER

     

     7,933,919 Shares of Common Stock (2)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     8,094,512 Shares of Common Stock (1) (2)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     6.8% (3)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    Consists of: 160,593 shares subject to stock options granted to Terrance McGuire in his capacity as a director of the Issuer that are exercisable as of the date of filing this Statement (as defined in Item 1 below) or within 60 days thereafter.

    (2)

    Consists of: (i) 3,120,194 shares held of record by Polaris V, (ii) 60,814 shares held of record by Polaris EF V, (iii) 21,374 shares held of record by Polaris FF V, (iv) 31,198 shares held of record by Polaris SFF V, (v) 4,202,679 shares held of record by Polaris IX and (vi) 497,660 shares held of record by Polaris HCT. PVMC V is the general partner of each of Polaris V, Polaris EF V, Polaris FF V and Polaris SFF V and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Polaris V, Polaris EF V, Polaris FF V and Polaris SFF V. The PVMC V Managing Members are the managing members of PVMC V and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Polaris V, Polaris EF V, Polaris FF V and Polaris SFF V. PPGP IX is the general partner of Polaris IX and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris IX. Terrance McGuire, an interest holder in PPGP IX and a member of the Issuer’s Board, and the PPGP IX Managing Members are the managing members of PPGP IX and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris IX. PHCT GP is the general partner of Polaris HCT and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris HCT. Terrance McGuire, an interest holder in PHCT GP and a member of the Issuer’s Board, and the PHCT GP Managing Members are the managing members of PHCT GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Polaris HCT.

    (3)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q, plus 160,593 shares subject to stock options held by Terrance McGuire and that are exercisable as of the date of the filing of this Statement or within 60 days thereafter.


    CUSIP No. 00534A102       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Jonathan Flint

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     3,233,580 Shares of Common Stock (1)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     3,233,580 Shares of Common Stock (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,233,580 Shares of Common Stock (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     2.7% (2)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    Consists of: (i) 3,120,194 shares held of record by Polaris V, (ii) 60,814 shares held of record by Polaris EF V, (iii) 21,374 shares held of record by Polaris FF V, and (iv) 31,198 shares held of record by Polaris SFF V. PVMC V is the general partner of each of Polaris V, Polaris EF V, Polaris FF V and Polaris SFF V and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Polaris V, Polaris EF V, Polaris FF V and Polaris SFF V. The PVMC V Managing Members are the managing members of PVMC V and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Polaris V, Polaris EF V, Polaris FF V and Polaris SFF V.

    (2)

    Based on 119,616,035 shares of Common Stock outstanding as of November 1, 2024, as set forth in the Form 10-Q.


    CUSIP No. 00534A102       13D

     

    Explanatory Note.

    This Amendment No. 4 (this “Amendment No. 4”) amends and supplements the Schedule 13D originally filed by the Reporting Persons with the Commission on August 20, 2021, as amended and supplemented on March 30, 2022, April 26, 2022, and June 24, 2022 (as amended, the “Original Schedule 13D”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 4 have the meanings ascribed to them in the Original Schedule 13D.

    Item 1. Security and Issuer.

    Item 1 of the Original Schedule 13D is hereby amended and restated in its entirety as set forth below:

    “This joint statement on Schedule 13D (this “Statement”) is filed with respect to the common stock, par value $0.0001 per share (“Common Stock”), of Invivyd, Inc. (previously known as Adagio Therapeutics, Inc.), a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 1601 Trapelo Road, Suite 178, Waltham, MA 02451.”

    Item 2. Identity and Background.

    Item 2(b) of the Original Schedule 13D is hereby amended and restated in its entirety as set forth below:

    “(b) The address of the principal offices of each Reporting Entity and the business address of each Reporting Individual is One Marina Park Drive, 8th Floor, Boston, MA 02210.”

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Original Schedule 13D is hereby supplemented and amended, as follows:

    (a) and (b) See Items 7-11 and 13 of the cover pages of this Amendment No. 4.

    (c) On December 9, 2024, Polaris IX sold 150,000 shares of Common Stock at a weighted average price per share of $0.6104 for aggregate proceeds of approximately $91,560.00.

    On December 10, 2024, Polaris IX sold 175,000 shares of Common Stock at a weighted average price per share of $0.5886 for aggregate proceeds of approximately $103,005.00.

    On December 11, 2024, Polaris IX sold 160,400 shares of Common Stock at a weighted average price per share of $0.5911 for aggregate proceeds of approximately $94,812.44.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: December 12, 2024

     

    POLARIS VENTURE PARTNERS V, L.P.
    By:   Polaris Venture Management Co. V, L.L.C.
    By:   *
    Authorized Signatory
    POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND V, L.P.
    By:   Polaris Venture Management Co. V, L.L.C.
    By:   *
    Authorized Signatory
    POLARIS VENTURE PARTNERS FOUNDERS’ FUND V, L.P.
    By:   Polaris Venture Management Co. V, L.L.C.
    By:   *
    Authorized Signatory
    POLARIS VENTURE PARTNERS SPECIAL FOUNDERS’ FUND V, L.P.
    By:   Polaris Venture Management Co. V, L.L.C.
    By:   *
    Authorized Signatory
    POLARIS VENTURE MANAGEMENT CO. V, L.L.C.
    By:   *
    Authorized Signatory
    POLARIS PARTNERS IX, L.P.
    By:   Polaris Partners GP IX, L.L.C.
    By:   /s/ Lauren Crockett
    Name:   Lauren Crockett
    Title:   General Counsel


    POLARIS PARTNERS GP IX, L.L.C.
    By:   /s/ Lauren Crockett
    Name:   Lauren Crockett
    Title:   General Counsel
    POLARIS HEALTHCARE TECHNOLOGY OPPORTUNITIES FUND, L.P.
    By:   Polaris Healthcare Technology Opportunities Fund GP, L.L.C.
    By:   /s/ Lauren Crockett
    Name:   Lauren Crockett
    Title:   General Counsel
    POLARIS HEALTHCARE TECHNOLOGY OPPORTUNITIES FUND GP, L.L.C.
    By:   /s/ Lauren Crockett
    Name:   Lauren Crockett
    Title:   General Counsel
    TERRANCE MCGUIRE
    By:   *
    Authorized Signatory
    JONATHAN FLINT
    By:   *
    Authorized Signatory
    *By:   /s/ Lauren Crockett
    Name:   Lauren Crockett
      Attorney-in-Fact

    [* This Amendment was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.]

    Get the next $IVVD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVVD

    DatePrice TargetRatingAnalyst
    4/5/2024$9.00Neutral → Buy
    Guggenheim
    3/26/2024$4.00 → $10.00Equal-Weight → Overweight
    Morgan Stanley
    12/19/2023$1.00 → $4.00Underweight → Equal-Weight
    Morgan Stanley
    5/1/2023$5.00Buy
    H.C. Wainwright
    More analyst ratings

    $IVVD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

      WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link and are advised to join 15 minutes prior to the start time. A replay of the webcast will be available via the company's investor relations website approximately two

      5/8/25 7:01:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

      WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank. The deal allows for drawdown of capital in the future if certain conditions and milestones are met. "We are pleased to have secured this term loan facility ahead of important anticipated catalysts, including gaining alignment with the FDA on the regulatory pathway of our pipeline candidate, VYD2311," said Bill Duke, Chief Financial Officer of Invivyd. "The non-dilutive nature of

      4/21/25 7:01:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

      WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan's investment firm, Mithril, is a significant long-term holder of Invivyd stock, and Mr. Royan led the 2022 shareholder action that focused Invivyd on its mission to deliver protection from serious viral infectious diseases, starting with COVID-19. "We are delighted by Ajay's return to the Board of Invivyd as the company prepares to take the next step forward in scaling the medica

      3/26/25 4:15:46 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Invivyd upgraded by Guggenheim with a new price target

      Guggenheim upgraded Invivyd from Neutral to Buy and set a new price target of $9.00

      4/5/24 7:50:41 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Invivyd from Equal-Weight to Overweight and set a new price target of $10.00 from $4.00 previously

      3/26/24 8:01:17 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Invivyd from Underweight to Equal-Weight and set a new price target of $4.00 from $1.00 previously

      12/19/23 7:28:14 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    SEC Filings

    See more
    • Invivyd Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Invivyd, Inc. (0001832038) (Filer)

      4/25/25 4:06:24 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Invivyd, Inc. (0001832038) (Filer)

      4/21/25 7:08:09 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Invivyd Inc.

      DEFA14A - Invivyd, Inc. (0001832038) (Filer)

      4/7/25 4:23:04 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

      SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

      12/12/24 4:39:09 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

      SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

      11/14/24 4:30:58 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

      SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

      11/14/24 9:16:35 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Royan Ajay

      4 - Invivyd, Inc. (0001832038) (Issuer)

      3/26/25 5:28:41 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Royan Ajay claimed ownership of 11,241,580 shares (SEC Form 3)

      3 - Invivyd, Inc. (0001832038) (Issuer)

      3/26/25 5:25:20 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Legal Officer, Secretary Andersen Jill

      4 - Invivyd, Inc. (0001832038) (Issuer)

      2/19/25 4:32:33 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    Financials

    Live finance-specific insights

    See more
    • Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

      WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link and are advised to join 15 minutes prior to the start time. A replay of the webcast will be available via the company's investor relations website approximately two

      5/8/25 7:01:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various operational efficiency improvementsPEMGARDA Fact Sheet updated to properly reflect neutralization activity of PEMGARDA against current circulating variants tested; on track for continued growth now reflective of ongoing commercial optimizationNext generation molecule VYD2311 first-in-human clinical trial dosing began in August 2024 with anticipated preliminary data readout late Q4 2024Management to host conference call t

      11/14/24 7:05:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

      WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 14, 2024, at 8:30 a.m. ET to discuss its financial results for the third quarter ended September 30, 2024, and provide recent business highlights. Invivyd reported preliminary third quarter 2024 results via press release on October 29, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link and are advised to join 15 minutes prior to the start time.

      11/6/24 7:01:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IVVD
    Leadership Updates

    Live Leadership Updates

    See more
    • Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

      WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan's investment firm, Mithril, is a significant long-term holder of Invivyd stock, and Mr. Royan led the 2022 shareholder action that focused Invivyd on its mission to deliver protection from serious viral infectious diseases, starting with COVID-19. "We are delighted by Ajay's return to the Board of Invivyd as the company prepares to take the next step forward in scaling the medica

      3/26/25 4:15:46 PM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

      Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and AmylyxAppointment intended to accelerate the addition of commercial capabilities associated with orphan medicines to the ongoing PEMGARDA™ commercial launchWilliam Duke, Jr., Chief Financial Officer, appointed as Principal Executive Officer WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) --  Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Timothy Lee will be appointed Invivyd's Chief Commercial Officer and will join the company's executive leadership team. Mr. Lee's appointment follows th

      5/31/24 7:00:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invivyd Elects Two New Independent Members to its Board of Directors

      WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, were elected to its Board of Directors at the annual meeting of stockholders on May 21, 2024. Dr. Gupta will serve as the Chairperson of the Compensation Committee and Mr. McLaughlin will serve as the Chairperson of the Audit Committee. "We are delighted to welcome Dr. Gupta and Mr. McLaughlin to our Board during a transformational period of growth for the company," said Marc Elia, Chairman of the Invivyd Board of Direc

      5/22/24 7:00:00 AM ET
      $IVVD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care